Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:CVAC NASDAQ:HOOD NASDAQ:MRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$50.36+0.9%$50.88$35.38▼$78.48$4.86B1.741.82 million shs1.55 million shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/AHOODRobinhood Markets$73.64-3.0%$76.11$62.63▼$153.86$66.31B2.2925.37 million shs20.70 million shsMRNAModerna$46.88-0.8%$50.82$22.28▼$59.55$18.60B1.058.07 million shs4.22 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%+4.03%-8.74%-5.80%+36.14%CVACCureVac0.00%0.00%0.00%0.00%+19.49%HOODRobinhood Markets0.00%-4.54%-11.85%-3.25%+15.31%MRNAModerna0.00%-4.40%-11.30%-6.00%+81.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$50.36+0.9%$50.88$35.38▼$78.48$4.86B1.741.82 million shs1.55 million shsCVACCureVac$4.66$4.66$3.13▼$5.72$1.05B1.77992,546 shsN/AHOODRobinhood Markets$73.64-3.0%$76.11$62.63▼$153.86$66.31B2.2925.37 million shs20.70 million shsMRNAModerna$46.88-0.8%$50.82$22.28▼$59.55$18.60B1.058.07 million shs4.22 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%+4.03%-8.74%-5.80%+36.14%CVACCureVac0.00%0.00%0.00%0.00%+19.49%HOODRobinhood Markets0.00%-4.54%-11.85%-3.25%+15.31%MRNAModerna0.00%-4.40%-11.30%-6.00%+81.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.53Moderate Buy$65.4730.01% UpsideCVACCureVac 1.80Reduce$6.8346.64% UpsideHOODRobinhood Markets 2.64Moderate Buy$107.8846.49% UpsideMRNAModerna 1.84Reduce$35.73-23.78% DownsideCurrent Analyst Ratings BreakdownLatest MRNA, CRSP, CVAC, and HOOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026CRSPCRISPR Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$50.00 ➝ $56.005/11/2026CRSPCRISPR Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$76.005/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.005/4/2026MRNAModerna UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$36.00 ➝ $45.005/4/2026MRNAModerna Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$35.00 ➝ $38.005/1/2026MRNAModerna The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$43.00 ➝ $49.005/1/2026MRNAModerna Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.004/30/2026HOODRobinhood Markets ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$102.00 ➝ $90.004/29/2026HOODRobinhood Markets Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$155.004/29/2026HOODRobinhood Markets Keefe, Bruyette & WoodsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Perform$75.00 ➝ $65.004/29/2026HOODRobinhood Markets Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$110.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$3.51M1,383.82N/AN/A$18.81 per share2.68CVACCureVac$70.74M14.78$0.99 per share4.73$3.36 per share1.39HOODRobinhood Markets$4.47B14.83$2.18 per share33.71$10.76 per share6.84MRNAModerna$1.94B9.57N/AN/A$18.67 per share2.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)CVACCureVac$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/AHOODRobinhood Markets$1.88B$2.0735.5828.652.3941.12%21.39%4.73%7/29/2026 (Estimated)MRNAModerna-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)Latest MRNA, CRSP, CVAC, and HOOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million5/1/2026Q1 2026MRNAModerna-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million4/28/2026Q1 2026HOODRobinhood Markets$0.3853$0.38-$0.0053$0.38$1.14 billion$1.07 billion3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/AHOODRobinhood MarketsN/AN/AN/AN/AN/AMRNAModernaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR Therapeutics0.3217.9717.96CVACCureVac0.033.703.69HOODRobinhood MarketsN/A1.221.22MRNAModerna0.082.412.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%CVACCureVac17.26%HOODRobinhood Markets93.27%MRNAModerna75.33%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%CVACCureVac2.15%HOODRobinhood Markets14.47%MRNAModerna10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableCVACCureVac880224.34 million219.52 millionOptionableHOODRobinhood Markets2,900900.51 million770.20 millionOptionableMRNAModerna4,700396.79 million353.93 millionOptionableMRNA, CRSP, CVAC, and HOOD HeadlinesRecent News About These CompaniesModerna’s mRNA flu shot to get FDA reviewMay 24 at 8:24 AM | thehill.comTNoubar Afeyan Sells 9,263 Shares of Moderna (NASDAQ:MRNA) StockMay 24 at 4:57 AM | americanbankingnews.comModerna (NASDAQ:MRNA) Director Sells $433,878.92 in StockMay 23 at 8:24 AM | insidertrades.comInsider Selling: Moderna (NASDAQ:MRNA) Director Sells $433,878.92 in StockMay 22 at 7:12 PM | marketbeat.comUSFDA to Convene Expert Panel Review for Moderna's mRNA Flu VaccineMay 22 at 2:58 PM | medicaldialogues.inMFDA plans rare advisory hearing to debate Moderna’s flu shotMay 22 at 9:57 AM | msn.comJames Mock Joins Moderna as Chief Financial OfficerMay 22 at 9:57 AM | finance.yahoo.comModerna mRNA flu vaccine to get FDA panel reviewMay 22 at 9:57 AM | yahoo.comModerna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue Rules - What's ChangedMay 22 at 9:57 AM | finance.yahoo.comModerna, Inc. (NASDAQ:MRNA) Receives Average Rating of "Reduce" from AnalystsMay 22 at 2:48 AM | americanbankingnews.comMRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu ShotMay 21 at 6:19 PM | stocktwits.comSModerna, Merck cancer combo cuts melanoma spread risk at five yearsMay 21 at 5:03 PM | reuters.comUS FDA to hold expert committee meeting to review Moderna's flu vaccineMay 21 at 1:19 PM | msn.comModerna to face FDA AdCom review for flu shotMay 21 at 1:19 PM | msn.comForget Moderna: This Biotech Juggernaut Is a Way Better Buy Right NowMay 21 at 9:36 AM | 247wallst.comPfizer, Moderna COVID vaccines 70% to 76% effective against severe illness in kids in 2022, data suggestMay 19, 2026 | cidrap.umn.eduCHHS cancels funding for Moderna vaccines to fight pandemic fluMay 19, 2026 | msn.comModerna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19, 2026 | seekingalpha.comModerna (NASDAQ:MRNA) President Stephen Hoge Sells 53,336 SharesMay 19, 2026 | insidertrades.comModerna Reports Second Quarter 2025 Financial Results and Provides Business UpdatesMay 18, 2026 | freep.comFModerna Reports Third Quarter 2025 Financial Results and Provides Business UpdatesMay 17, 2026 | freep.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Robinhood, SoFi, and Webull Are Telling Very Different StoriesBy Peter Frank | May 17, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026MRNA, CRSP, CVAC, and HOOD Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$50.36 +0.46 (+0.92%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$50.15 -0.21 (-0.41%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.CureVac NASDAQ:CVAC$4.66 0.00 (0.00%) As of 05/22/2026CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Robinhood Markets NASDAQ:HOOD$73.64 -2.28 (-3.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$73.31 -0.33 (-0.45%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Robinhood Markets, Inc. operates financial services platform in the United States. Its platform allows users to invest in stocks, exchange-traded funds (ETFs), American depository receipts, options, gold, and cryptocurrencies. The company offers fractional trading, recurring investments, fully-paid securities lending, access to investing on margin, cash sweep, instant withdrawals, retirement program, around-the-clock trading, and initial public offerings participation services. It also provides various learning and education solutions comprise Snacks, an accessible digest of business news stories for a new generation of investors.; Learn, which is an online collection of beginners' guides, feature tutorials, and financial dictionary; Newsfeeds that offer access to free, premium news from sites from various sites, such as Barron's, Reuters, and Dow Jones. In addition, the company offers In-App Education, a resource that covers investing fundamentals, including why people invest, a stock market overview, and tips on how to define investing goals, as well as allows customers to understand the basics of investing before their first trade; and Crypto Learn and Earn, an educational module available to various crypto customers through Robinhood Learn to teach customers the basics related to cryptocurrency. Further, it provides Robinhood credit cards, cash card and spending accounts, and wallets. Robinhood Markets, Inc. was incorporated in 2013 and is headquartered in Menlo Park, California.Moderna NASDAQ:MRNA$46.88 -0.38 (-0.80%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$46.89 +0.01 (+0.02%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
